Clinical Trial Identifier: NCT06732180
Status: Recruiting
Sponsor: Gain Therapeutics, Inc.
Phase: Phase 1
Intervention: GT-02287 (oral, once daily)
This Phase 1 clinical trial evaluates the safety, tolerability, pharmacokinetics, and pharmacodynamics of GT-02287 in patients with Parkinson's Disease.
GT-02287 is a novel protein stabilizer being developed for Parkinson's Disease. The compound targets protein misfolding, a key pathological feature in neurodegenerative diseases. By stabilizing native protein conformations, GT-02287 may help protect neurons from toxic aggregation.
Gain Therapeutics uses a proprietary computer-aided drug design platform to identify allosteric binding sites and develop small molecules that stabilize properly folded proteins. This approach differs from traditional enzyme inhibitors and aims to address the root cause of protein misfolding in PD.
Protein misfolding and aggregation are central to Parkinson's disease pathogenesis, particularly involving alpha-synuclein[1]. GT-02287 represents a novel mechanism targeting the upstream process of protein aggregation rather than downstream symptoms.
Most drug development targets enzyme active sites or receptors. The protein stabilization approach by Gain Therapeutics takes a fundamentally different strategy[2]:
| Approach | Target | Example |
|---|---|---|
| Enzyme inhibition | Active site | MAO-B inhibitors |
| Receptor agonism/antagonism | Binding site | Dopamine agonists |
| Protein stabilization | Allosteric sites | GT-02287 |
Gain Therapeutics uses a proprietary platform combining:
This approach has identified novel binding sites not visible through traditional methods, enabling development of molecules that stabilize protein conformation.
In PD, the protein alpha-synuclein undergoes:
GT-02287 acts by:
| Compound | Indication | Stage | Mechanism |
|---|---|---|---|
| GT-02287 | Parkinson's Disease | Phase 1 | Protein stabilizer |
| GT-02288 | Tauopathies | Preclinical | Protein stabilizer |
| GT-01179 | ALS | Discovery | Protein stabilizer |
Primary endpoints include safety and tolerability assessments. Pharmacokinetic and pharmacodynamic markers will characterize drug exposure and biological effects in blood and cerebrospinal fluid[3].
Alpha-synuclein structure, function, and dysfunction in Parkinson's disease. Neuron. 2023. ↩︎
Protein misfolding in neurodegenerative diseases: mechanisms and therapeutic targets. Nature Reviews Drug Discovery. 2024. ↩︎
GT-02287: A novel protein stabilizer for Parkinson's disease. Journal of Parkinson's Disease. 2024. ↩︎